Product Description
Remimazolam, a novel benzodiazepine created out of so-called soft drug development, is an ultrashort-acting intravenous sedative-hypnotic currently being investigated in clinical trials. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/27496519/)
Mechanisms of Action: GABA Modulator
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Approved
Approved Countries: Austria | Belgium | Croatia | Czech | Estonia | European Medicines Agency | Finland | Germany | Greece | Hungary | Iceland | Ireland | Italy | Japan | Korea | Latvia | Lithuania | Netherlands | Norway | Poland | Portugal | Romania | Slovakia | Slovenia | Sweden | Taiwan | United Kingdom | United States
Approved Indications: None
Known Adverse Events: None
Company: Jiangsu Hengrui Medicine Co
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, China
Active Clinical Trial Count: 7
Highest Development Phases
Phase 3: Other
Phase 2: COVID-19
Phase 1: Healthy Volunteers
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| 2020-004118-37 | P3 |
Active, not recruiting |
Other |
2025-02-28 |
|
| HR7056-302 | P3 |
Completed |
Other |
2024-08-13 |
|
| HR7056-206 | P2 |
Recruiting |
Other |
2023-11-01 |
24% |
| HR7056-205 | P2 |
Completed |
Other |
2023-04-02 |